{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:40:45Z","timestamp":1760776845185,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003761","name":"Universitair Medisch Centrum Utrecht","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nmd.2020.09.026","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T10:30:33Z","timestamp":1600597833000},"page":"915-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases"],"prefix":"10.1016","volume":"30","author":[{"given":"Louise","family":"Gaboriau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Davion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Combret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Rouby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Morell-Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1476-5381.2010.01099.x","article-title":"Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors","volume":"162","author":"Mewar","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.nmd.2020.09.026_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-\u03b1 inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"9","key":"10.1016\/j.nmd.2020.09.026_bib0003","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrd1175","article-title":"Anti-TNF-alpha therapies: the next generation","volume":"2","author":"Palladino","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2020.09.026_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14740338.2016.1145653","article-title":"A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease","volume":"15","author":"Papamichael","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.nmd.2020.09.026_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14740338.2016.1160054","article-title":"The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis","volume":"15","author":"Hern\u00e1ndez","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.nmd.2020.09.026_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40257-013-0053-5","article-title":"Safety and tolerability of tumor necrosis factor-\u03b1 inhibitors in psoriasis: a narrative review","volume":"15","author":"Semble","year":"2014","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A Systematic Review and Meta-Analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"10.1016\/j.nmd.2020.09.026_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","article-title":"Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature","volume":"37","author":"Shovman","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.nmd.2020.09.026_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.nmd.2020.09.026_bib0012","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2020.09.026_bib0013","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.nmd.2020.09.026_bib0014","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med"},{"issue":"8","key":"10.1016\/j.nmd.2020.09.026_bib0016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00247-014-2951-y","article-title":"All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia","volume":"44","author":"Pecker","year":"2014","journal-title":"Pediatr Radiol"},{"issue":"7","key":"10.1016\/j.nmd.2020.09.026_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/RHU.0b013e31818866d8","article-title":"All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis","volume":"15","author":"Yu","year":"2009","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.nmd.2020.09.026_bib0018","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1751-553X.2007.00933.x","article-title":"All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia","volume":"30","author":"Oliveira","year":"2008","journal-title":"Int J Lab Hematol"},{"issue":"8 Suppl","key":"10.1016\/j.nmd.2020.09.026_bib0019","first-page":"ECR35","article-title":"All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia","volume":"91","author":"Citak","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.nmd.2020.09.026_bib0020","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1212\/WNL.54.11.2186","article-title":"Myositis during long-term interferon-alpha treatment","volume":"54","author":"Hengstman","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2020.09.026_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002960050103","article-title":"Polymyositis occurring during \u03b1-interferon treatment for malignant melanoma: a case report and review of the literature","volume":"19","author":"Cirigliano","year":"1999","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.nmd.2020.09.026_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00296-017-3821-3","article-title":"Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review","volume":"38","author":"Borges","year":"2018","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0023","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nmd.2020.09.026_bib0024","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.nmd.2020.09.026_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mus.21164","article-title":"Immune-mediated myositis in Crohn's disease","volume":"39","author":"Shimoyama","year":"2009","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2020.09.026_bib0026","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1023\/A:1018825301263","article-title":"Inflammatory myositis in association with inflammatory bowel disease","volume":"42","author":"Kulkarni","year":"1997","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.nmd.2020.09.026_bib0027","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.rbr.2015.12.005","article-title":"Three cases of anti-TNF induced myositis and literature review","volume":"57","author":"Zengin","year":"2016","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.nmd.2020.09.026_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2015-213577","article-title":"E.tanercept-induced myositis: do we have to stop it? A surprising outcome","volume":"2016","author":"Tariq","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.nmd.2020.09.026_bib0029","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.nmd.2020.09.026_bib0030","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jdv.13246","article-title":"TNF-\u03b1: a treatment target or cause of sarcoidosis?","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.nmd.2020.09.026_bib0031","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1152\/japplphysiol.01453.2005","article-title":"Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle","volume":"101","author":"Peterson","year":"2006","journal-title":"J Appl Physiol"},{"issue":"3","key":"10.1016\/j.nmd.2020.09.026_bib0032","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2006.07.003","article-title":"Tumor Necrosis Factor-\u03b1 in inflammatory myopathies: pathophysiology and therapeutic implications","volume":"36","author":"Efthimiou","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.nmd.2020.09.026_bib0033","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.nmd.2020.09.026_bib0034","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00415-011-5907-2","article-title":"Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies","volume":"258","author":"St\u00fcbgen","year":"2011","journal-title":"J Neurol"},{"issue":"3\u20134","key":"10.1016\/j.nmd.2020.09.026_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2020.09.026_bib0036","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2020.09.026_bib0037","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.nmd.2020.09.026_bib0038","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor-inhibitor associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.nmd.2020.09.026_bib0039","article-title":"Associations between TNF-\u03b1-308A\/G polymorphism and susceptibility with dermatomyositis: a meta-analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620305897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620305897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:08Z","timestamp":1760775008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620305897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0960896620305897"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.09.026","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}